# CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)

> **NCT07254962** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sir Mortimer B. Davis - Jewish General Hospital** · enrollment: 75 (estimated)

## Conditions studied

- Head Neck Cancer
- Mouth Cancer
- Throat Cancer
- Larynx Cancer
- Skin Cancer Face

## Interventions

- **DRUG:** Capecitabine
- **OTHER:** Standard of Care (SOC)

## Key facts

- **NCT ID:** NCT07254962
- **Lead sponsor:** Sir Mortimer B. Davis - Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2031-01-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-11-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07254962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07254962, "CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07254962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*